➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
McKesson
Harvard Business School
Boehringer Ingelheim
Moodys

Last Updated: September 16, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR HORIZANT

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Horizant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01668667 ↗ Gabapentin Enacarbil (GSK1838262) Adult Restless Leg Syndrome Post Marketing Commitment Study Completed XenoPort, Inc. Phase 4 2012-06-01 Gabapentin enacarbil (GEn; GSK1838262; HORIZANT), at a dose of 600 mg/day, is currently approved in the United States for the treatment of adults with moderate-to-severe primary Restless Legs Syndrome (RLS). The aim of this study is to compare the efficacy, tolerability, and safety of GEn at lower doses (450 and 300 mg/day) as well as the already approved dose of 600 mg/day versus placebo for the treatment of subjects with moderate to severe primary RLS. This study is being conducted as a post-marketing commitment (PMC) as a condition of the approval of HORIZANT tablets (NDA 022399).
NCT02117076 ↗ Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome Terminated Theresa Zesiewicz Phase 4 2014-04-01 The study will compare the safety, effectiveness and tolerability of gabapentin (Neurontin) versus gabapentin enacarbil (Horizant) as treatment restless leg syndrome.
NCT02252536 ↗ HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder Active, not recruiting XenoPort, Inc. Phase 2 2015-06-01 The purpose of this study is to determine whether gabapentin enacarbil is effective in the treatment of problems with alcohol.
NCT02252536 ↗ HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder Active, not recruiting National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 2 2015-06-01 The purpose of this study is to determine whether gabapentin enacarbil is effective in the treatment of problems with alcohol.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Horizant

Condition Name

Condition Name for Horizant
Intervention Trials
RLS 3
Restless Legs Syndrome 3
Alzheimer Disease 1
Alcohol Use Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Horizant
Intervention Trials
Restless Legs Syndrome 8
Psychomotor Agitation 4
Syndrome 4
Head and Neck Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Horizant

Trials by Country

Trials by Country for Horizant
Location Trials
United States 52
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Horizant
Location Trials
California 5
South Carolina 4
Pennsylvania 4
Tennessee 4
Florida 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Horizant

Clinical Trial Phase

Clinical Trial Phase for Horizant
Clinical Trial Phase Trials
Phase 4 6
Phase 3 1
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Horizant
Clinical Trial Phase Trials
Recruiting 5
Not yet recruiting 2
Active, not recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Horizant

Sponsor Name

Sponsor Name for Horizant
Sponsor Trials
XenoPort, Inc. 6
Theresa Zesiewicz 1
University of Texas at Austin 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Horizant
Sponsor Trials
Industry 6
Other 6
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
AstraZeneca
Medtronic
McKinsey
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.